IP Verse

Astellas Pharma Inc. patent opposition analysis

Latest patents of Astellas Pharma Inc. opposed by its competitors

The following table provides an overview of the latest patents of Astellas Pharma Inc. that has been opposed by its competitors. It provides an insight into the competitive landscape of the industry and highlights the patents that are subject to oppositions.

Patent NumberGrant DateTitleTotal Oppositions
EP3791896Jan 10, 2024Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer3
EP3318259Jan 11, 2023Stable Pharmaceutical Composition For Oral Administration2
EP3725810Jul 6, 2022Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer2
EP3725778Aug 18, 2021Formulations Of Enzalutamide11
EP2345410Dec 30, 2020Controlled Release Pharmaceutical Composition6
EP3254695Sep 9, 2020Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer1
EP2824181Nov 14, 2018Novel Fgfr3 Fusion Product2
EP2554168Jan 24, 2018Controlled Release Pharmaceutical Composition4

Top competitors of Astellas Pharma Inc.